EDAP TMS SA ADR(EDAP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.82 | Insider Own | 0.18% | Shs Outstand | 37.5M | Perf Week | -0.23% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | 25.16% | Insider Trans | 17.4% | Shs Float | 37.4M | Perf Month | 30.51% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.23 | Inst Own | 38.85% | Short Float | 0.15% | Perf Quarter | -1.14% |
| Income | -0.03B | P/S | 2.18 | EPS this Y | -11.79% | Inst Trans | 0.13% | Short Ratio | 1.56 | Perf Half Y | 79.25% |
| Sales | 0.07B | P/B | 16.03 | EPS next 5Y | 12.52% | ROA | -40.21% | Short Interest | 0.06M | Perf YTD | 31.31% |
| Book/sh | 0.27 | P/C | 10.79 | EPS past 3/5Y | -106.02% -63.72% | ROE | -130.05% | 52W High | -14.46% ($5.05) | Perf Year | 141.34% |
| Cash/sh | 0.4 | P/FCF | - | Sales past 3/5Y | 6.9% 8.3% | ROIC | -102.4% | 52W Low | 257.02% ($1.21) | Perf 3Y | -57.27% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -43.38% | Gross Margin | 44.64% | Volatility(W/M) | 6.1% 7.02% | Perf 5Y | -36% |
| Dividend TTM | - | EV/Sales | 2.36 | Sales Y/Y TTM | - | Oper. Margin | -34.67% | ATR (14) | 0.27 | Perf 10Y | 23.43% |
| Dividend Ex-Date | - | Quick Ratio | 0.99 | EPS Q/Q | -22.15% | Profit Margin | -41.5% | RSI (14) | 62.01 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.34 | Sales Q/Q | 25.28% | SMA20 | 6.14% ($4.07) | Beta | -0.01 | Target Price | $5.83 |
| Payout | - | Debt/Eq | 2.75 | Earnings | 2026/5/7 | SMA50 | 16.14% ($3.72) | Rel Volume | 1.53 | Prev Close | $4.2 |
| Employees | 289 | LT Debt/Eq | 1.98 | EPS/Sales Surpr. | -17.13% 7.39% | SMA200 | 37.2% ($3.15) | Avg Volume(3M) | 0.04M | Price | $4.32 |
| IPO | 1997/8/1 | Option/Short | Yes/Yes | Trades | 559 | Volume | 55,874 | Change | 2.86% |
🩺 A France-based medical device company that develops non-invasive treatment equipment using High-Intensity Focused Ultrasound (HIFU) technology. Its flagship product is the Focal One system for prostate cancer treatment, and the company supplies its devices to hospitals and urology centers worldwide, including in the United States. This microcap has carved out a distinctive position in the field of robotic energy-based treatments.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded more than usual. That is 153% of its average volume.
EDAP has weak earning power
Of every $100 in sales, $34.67 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -11.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $218. Peers typically go for $245.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -36.0%. The S&P 500 did +55% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 38.9%.
Tap to view numbers
It ranks #6 of 12 in the industry
Based on market cap of $162M.
FAQ
What kind of company is EDAP?
EDAP belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of EDAP?
The market cap of EDAP is approximately $162M, ranking 4,261 within its sector.
What is the 52-week high and low for EDAP?
EDAP has recorded a 52-week high of $5.05 and a low of $1.21.